SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Genesys (CEGE)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: david james who wrote (845)4/3/2000 4:56:00 PM
From: Bosco  Read Replies (1) of 1298
 
Hi david, not that I mind CEGE sporting a single digit p/e, but the street usually discounts the one-time events like gain on sale of securities. Of course, similar treatment is extended to one-time losses too.

However, assuming the p/e is heavily discounted, I think CEGE should deserve a far richer valuation model based on 1) the ongoing developments like the clinical trials; 2) CEGE's patent portfolio, which can be a recurring revenue driver; and 3) her underlying financial strength as the revenue streams from products and licensings come to fruition.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News